Tuesday, 7 July 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 07 July 2026
News

Novartis buys Aussie-backed firm

Posted 7 July 2026 PM

Novartis has agreed to pay more than $2 billion for Myricx Bio in a major windfall for the company’s founding investor, Australian venture capital firm Brandon Capital.

Myricx Bio is developing a new class of antibody-drug conjugates (ADCs) using N-myristoyltransferase inhibitor (NMTi) payloads, aimed at addressing toxicity challenges associated with current treatments.

To see the whole article, please login

Popular

Blockbusters stuck in PBS limbo
Pharma Wonderland opens in Sydney
Next era of blockbusters unveiled
New FY brings fresh career start
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (23)

Access & Reimbursement (1)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (4)

Other (8)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home